中文名 | Vonafexor |
英文名 | 4-chloro-5-[4-(2,6-dichlorobenzene-1- sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid |
别名 | 化合物VONAFEXOR |
英文别名 | YP001 PXL007 PLX007 EYP-001 Vonafexor Vonafexor(PLX007,EYP-001) 2-Benzofurancarboxylic acid, 4-chloro-5-[4-[(2,6-dichlorophenyl)sulfonyl]-1-piperazinyl]- 4-chloro-5-[4-(2,6-dichlorobenzene-1- sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid |
CAS | 1192171-69-9 |
化学式 | C19H15Cl3N2O5S |
分子量 | 489.76 |
密度 | 1.604±0.06 g/cm3(Predicted) |
沸点 | 680.5±65.0 °C(Predicted) |
溶解度 | 溶于DMSO |
酸度系数 | 3.05±0.30(Predicted) |
存储条件 | -20℃ |
产品用途 | Vonafexor, also known as EYP001, is a farnesoid X receptor agonist. Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) for which therapy is suboptimal. The farnesoid-X-receptor (FXR) and the G protein bile acid receptor (GPBAR)1 are two bile acid-activated receptors that exert regulatory effects on lipid, glucose, energy, and immune homeostasis. GPBAR1 and FXR ligands have shown efficacy in reversing steatohepatitis and fibrosis in preclinical models of NASH. |
靶点 | FXR |
参考资料 展开查看 | Orrico M, Ronchey S, Setacci C, et al. The "Destino-guided BEVAR" to Catheterize Downward Branches from a Femoral Access: Technical Note and Case Report. Ann Vasc Surg. 2019;57:266-271. doi:10.1016/j.avsg.2018.09.044 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.042 ml | 10.209 ml | 20.419 ml |
5 mM | 0.408 ml | 2.042 ml | 4.084 ml |
10 mM | 0.204 ml | 1.021 ml | 2.042 ml |
5 mM | 0.041 ml | 0.204 ml | 0.408 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!